Specifically, it was not until 2014 that the guidelines from Japanese Lung Cancer Society recommended EGFR-TKI over cytotoxic chemotherapy as first-line therapy for patients with EGFR-mutated advanced NSCLC, in alignment with the guidelines from ESMO and NCCN. The gene discussed is EGFR; the disease is lung carcinoma.